



มหาวิทยาลัยมหิดล
คณะแพทยศาสตร์
ศิริราชพยาบาล



Interhospital Endocrine Conference

24/3/66

ศิริราชพยาบาล



Pathophysiology



This set point is increased (shifted rightward)



Clinical Presentation

- While **typically asymptomatic**, FHH has been associated with at least a **few clinically significant manifestations**, particularly in those who come to medical attention
- In the earlier analyses of index cases and their kindreds, those who had FHH (genotype unknown at the time) with **mild hypercalcemia** reported more symptoms of muscle weakness, fatigue, arthralgias, and increased thirst than their normocalcemic relatives
- Other **case reports** have described **acute pancreatitis, chondrocalcinosis, and even nephrolithiasis**, but a separate group has challenged the link between FHH and pancreatitis
- The phenotypes of these different subtypes of FHH are generally similar, aside from some reports of **more symptomatic disease** with certain cases of **FHH3 with AP2S1 mutations**




Differentiating FHH from PHPT

Feature	PHPT	FHH
Serum calcium	increased (mild to severe)	increased (mild)
Symptoms of hypercalcemia	absent, present	absent, present (FHH3)
Complications of hypercalcemia	absent, present	absent, present (FHH3)
Previous normocalcemia	present	absent
Parathyroid hormone	normal (10%), elevated (90%)	normal (80%), elevated (20%)
Phosphorus	normal or decreased	normal
Magnesium	normal or decreased	normal or elevated
Calcium to creatinine clearance ratio	> 0.02	< 0.01
Family history	none	present (70-85%)
Neck ultrasonography	adenoma	negative
Pathologic findings	adenoma or hyperplasia	normal or mild hyperplasia



Calcium/Creatinine Clearance Ratio



The optimal **cut-off point** for diagnosing FHH using CCCR was < 0.0115 , which yielded

- a **sensitivity** of **0.80**
- a **specificity** of **0.88**


Overlap analysis revealed that a **cut-off point** for **CCCR** at < 0.020 would

- sample **98%** (53/54) of all patients with **FHH**
- include **35%** (34/97) of the **PHPT** patients



- FHH1 has almost **complete penetrance** and follows an **autosomal dominant** pattern of disease inheritance
- The majority of cases are FHH1, due to **heterozygous inactivating mutations in CASR on chromosome 3**
- **Sporadically occurring new mutations** are not uncommon either occurring in **15-30%** of new index cases


Genetics & Subtypes





Differentiating FHH from PHPT

Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop





Prognosis & Treatment

- The **majority** of cases of FHH do **not require any treatment**, and morbidity is often a result of inappropriate surgical intervention
- **Calcimimetics** can be offered to adults with FHH and those in whom the **serum calcium level is 1 mg/dL beyond the upper limit of normal** or with **possible symptoms of hypercalcemia**
 - FHH cases associated with recurrent pancreatitis
 - Successful normalization of serum calcium concentrations
- **Subtotal parathyroidectomy** is generally **ineffective** and therefore not recommended
- **Total parathyroidectomy** is recommended only for the most severe cases, such as those with **NSHPT**, due to the obligatory resultant permanent hypoparathyroidism



Conclusion

- FHH should be considered on the differential diagnosis of asymptomatic hypercalcemia
- Calculation of the 24-h urine calcium/creatinine clearance ratio may guide the diagnostic evaluation of hypercalcemia, particularly in distinguishing FHH from PHPT
- Genetic studies should be pursued when urine calcium excretion is low or inappropriately normal for serum calcium levels, particularly in younger patients
- CASR mutations comprise the majority of FHH cases, but GNA11 and AP2S1 mutations should be considered in CASR-negative cases of suspected FHH
- Morbidity is generally low in FHH, although mild symptoms of hypercalcemia and pancreatitis have been reported, and chondrocalcinosis has been reported with higher frequency in FHH
- Calcimimetics can be considered in patients with symptomatic FHH
- Surgery should generally be avoided